133333-22-9

Upstream product

• 101669-80-1 methyl (3S,4S)-N-tert-butoxycarbonyl-4-amino-3-hydroxy-5-phenylpentanoate 
• 77-76-9 2,2-dimethoxy-propane 

Downstream Products

• 136630-94-9 (4S,5S)-4-Benzyl-5-(2-hydroxy-ethyl)-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester 
• 136630-95-0 (4S,5S)-4-Benzyl-5-(2-methanesulfonyloxy-ethyl)-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester 
• 136630-82-5 (4S,5S)-4-benzyl-5-(2-carboxyethyl)-2,2-dimethyloxazolidine-3-carboxylic acid tert-butyl ester 
• 136630-80-3 (S)-4-benzyl-5-(2-cyanoethyl)-2,2-dimethyloxazolidine-3-carboxylic acid tert-butyl ester 
• 136658-79-2 N_α-propanoyl>ACHPA>Ile N-<(4-amino-2-methyl-5-pyrimidinyl)methyl>amide 
• 120451-87-8 BOC-PheΨ<(S)-CHOHCH2>Gly-ACHPA-Ile N-<(4-amino-2-methyl-5-pyrimidinyl)methyl>amide 

Relevant academic research and scientific papers

Substrate Analogue Renin Inhibitors Containing Replacements of Histidine in P2 or Isosteres of the Amide Bond between P3 and P2 Sites

Incorporation of β-alanine or γ-aminobutyric acid in position P2 of ACHPA or LeuΨVal-based tetrapeptides gave highly active renin inhibitors (compounds V,VI, and XVII) with high specificity for renin and a remarkable stability against chymotrypsin.Replacement of the amide bond between P2 and P3 by isosteres (ketomethylenes, hydroxyethylenes, and the corresponding thio-insertion analogues) led to compounds (VIII-XIII, XVIII, and XIX) with renin inhibitory activity in the nanomolar range.Oral activity was achieved by incorporation of polar functionalities at the N-terminus of β-alanine-containing tetrapeptides.One of these compounds (XXVIII) was chosen for further studies.This inhibitor demonstrated excellent efficacy and a long duration of action after intravenous and oral administration to cynomolgus monkeys.